| 2025年中报 | 2024年年报 | 2024年中报 | 2023年年报 | 2023年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 多肽类产品(元) | 40,072,884.96 | 82,605,702.00 | 41,722,494.51 | 113,158,999.35 | 66,327,721.63 |
| 受托研发业务(元) | - | 40,289,445.68 | - | 12,471,569.10 | - |
| 受托业务(元) | 11,696,639.40 | - | 19,839,370.75 | - | - |
| 其他产品(元) | 28,840,484.04 | 46,599,545.61 | 31,013,567.48 | 105,429,135.92 | 63,430,055.95 |
| 其他业务收入(元) | - | - | - | - | 9,255,582.52 |
| 营业成本(元) | |||||
| 多肽类产品(元) | 21,439,150.46 | 35,456,374.22 | 16,535,690.30 | 33,557,821.18 | 17,676,117.09 |
| 受托研发业务(元) | - | 20,098,345.52 | - | 4,242,632.20 | - |
| 受托业务(元) | 6,415,866.01 | - | 8,260,950.34 | - | - |
| 其他产品(元) | 16,468,763.22 | 19,257,648.26 | 10,960,649.06 | 35,796,864.86 | 19,603,679.01 |
| 其他业务收入(元) | - | - | - | - | 2,555,846.94 |
| 毛利(元) | |||||
| 多肽类产品(元) | 18,633,734.50 | 47,149,327.78 | 25,186,804.21 | 79,601,178.17 | 48,651,604.54 |
| 受托研发业务(元) | - | 20,191,100.16 | - | 8,228,936.90 | - |
| 受托业务(元) | 5,280,773.39 | - | 11,578,420.41 | - | - |
| 其他产品(元) | 12,371,720.82 | 27,341,897.35 | 20,052,918.42 | 69,632,271.06 | 43,826,376.94 |
| 其他业务收入(元) | - | - | - | - | 6,699,735.58 |
| 毛利率(%) | |||||
| 多肽类产品(%) | 46.50 | 57.08 | 60.37 | 70.34 | 73.35 |
| 受托研发业务(%) | - | 50.12 | - | 65.98 | - |
| 受托业务(%) | 45.15 | - | 58.36 | - | - |
| 其他产品(%) | 42.90 | 58.67 | 64.66 | 66.05 | 69.09 |
| 其他业务收入(%) | - | - | - | - | 72.39 |
| 收入构成(%) | |||||
| 多肽类产品(%) | 49.71 | 48.74 | 45.07 | 48.97 | 47.71 |
| 受托研发业务(%) | - | 23.77 | - | 5.40 | - |
| 受托业务(%) | 14.51 | - | 21.43 | - | - |
| 其他产品(%) | 35.78 | 27.49 | 33.50 | 45.63 | 45.63 |
| 其他业务收入(%) | - | - | - | - | 6.66 |
| 毛利构成(%) | |||||
| 多肽类产品(%) | 51.35 | 49.80 | 44.33 | 50.55 | 49.05 |
| 受托研发业务(%) | - | 21.33 | - | 5.23 | - |
| 受托业务(%) | 14.55 | - | 20.38 | - | - |
| 其他产品(%) | 34.09 | 28.88 | 35.29 | 44.22 | 44.19 |
| 其他业务收入(%) | - | - | - | - | 6.76 |